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Abstract
Background Epidemiological studies have identified obesity
as a major risk factor for cancer in humans, and trials have
demonstrated a significant reduction in the incidence of cancer
after bariatric surgery. The rapidity of weight loss after bariat-
ric surgery provides an opportunity to identify the molecular
changes associated with effective obesity treatment.
Indirectly, this may provide some insights into the mecha-
nisms that drive the association between obesity and cancer.
We sought to measure circulating cancer-associated proteins
before and after laparoscopic sleeve gastrectomy (LSG).
Methods We prospectively enrolled 15 patients undergoing
LSG. Thirty-four plasma protein biomarkers thought to be
associated with cancer processes were analyzed at baseline
and following successful weight loss at 12 weeks using a
multiplex bead-based assay.
Results Mean excess body weight loss was 44 % at 12-week
follow-up. After LSG, a significant reduction in circulating
plasma levels was observed for half (17/34) of the proteins
assessed: VEGF-A, VEGF-C, VEGF-D, endoglin, PLGF,
sFASL, IGFBP-1, IL-18, prolactin, EGF, TGFα, sCD40L,
IL-18, TNFα, IL-6, HB-EGF, and PAI-1. Nonsignificant de-
creases were found for the remaining proteins.
Conclusions Circulating cancer-related biomarker levels were
reduced by surgical weight loss, and this benefit was achieved
as early as 3months after operation. The observed reduction in
cancer biomarkers may be related to the reported decrease in
cancer incidence following bariatric surgery.
Keywords Bariatric surgery . Neoplasms . Biological
markers . Gastrectomy . Neoplasms/prevention and control .
Laparoscopy
Abbreviations
EGF Epidermal growth factor
FGF-basic Basic fibroblast growth factor
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sVEGFR-1 Soluble vascular endothelial growth factor
receptor 1
sVEGFR-2 Soluble vascular endothelial growth factor
receptor 2
TGFα Transforming growth factor alpha
TNFα Tumor necrosis factor alpha
uPA Urokinase plasminogen activator
VEGF-A Vascular endothelial growth factor-A
VEGF-C Vascular endothelial growth factor-C
VEGF-D Vascular endothelial growth factor-D
Introduction
Obesity is one of the key issues facing human health, threatening
to reverse the incremental gains in life expectancy accrued in the
twentieth century [1]. This year, the World Health Organization
estimates that two billion adults worldwide are now either over-
weight (BMI > 25 kg/m2) or obese (BMI > 30 kg/m2).
Approximately 39 % of the world’s population thus has a mod-
erate to severe increase in their risk of acquiring obesity-related
comorbidities, of which type 2 diabetes mellitus (T2DM) is the
paradigm illness [2]. Large epidemiological studies have dem-
onstrated a gradient between excess bodyweight and the relative
risk of cancer [3], suggesting a causal association between in-
creased adiposity and the development of cancer. Obesity is now
considered amajor etiological factor in cancers of the esophagus
(adenocarcinoma), breast (postmenopausal), endometrium, co-
lon and rectum, kidney, pancreas, thyroid, and gallbladder [4]. It
is estimated that by 2030, obesity will be the major contributor
to the 50 % increase in the worldwide number of cancer cases,
overtaking tobacco use [5].
Bariatric surgery provides effective and enduring therapeutic
weight loss [6, 7]. Population-based studies have shown a reduc-
tion in cancer incidence andmortality following bariatric surgery
[8–10], suggesting a causal link between excess adiposity and
cancer. Proposed mechanisms leading to a tissue microenviron-
ment favorable for the development of cancer in the obese in-
clude a chronic, low-grade inflammatory state, increased expres-
sion of proangiogenic factors, secondary cell proliferation by
excess sex hormones and obesity hormones (adipokines),
hyperinsulinaemia, and increased oxidative stress [11, 12].
Previous bariatric surgery studies using serial blood sample
analysis have reported on multiple factors associated with car-
diovascular risk, insulin resistance, metabolic profile, and in-
flammation [13–16]. Despite the interest in bariatric surgery
and reduced cancer outcomes, relatively few reports in
humans have evaluated the serological changes in cancer-
related factors after bariatric surgery [17–21].
This study was undertaken to examine whether the blood
levels of cancer-related biomarkers are altered by surgical
weight loss. As well as contributing to the scientific basis of
bariatric surgery, it was anticipated that the results might




We recruited obese participants from a single center present-
ing for bariatric surgery to a single surgeon (RVL) in a tertiary
referral hospital. Inclusion criteria were age > 18 years and
BMI > 30 kg/m2 with obesity comorbid illness, or
BMI > 40 kg/m2. Exclusion criteria were any past or present
history of benign or malignant tumor or an inflammatory or
autoimmune disorder, and regular use of anti-inflammatory or
corticosteroid medications. Two study visits were scheduled:
the first at baseline prior to bariatric surgery and the second at
the routine 12-week postoperative follow-up.
A detailed clinical assessment, including comorbidities and
medication use, was made each visit. Anthropometric data
including height, weight, BMI, and excess body weight were
measured with patients barefoot. BMI was calculated as
weight/height × height (kg/m2). Excess body weight (EBW)
was calculated as weight above the ideal BMI of 25 kg/m2 and
converted to kilos. Clinical data including comorbidities and
medication use was extracted from patients’ medical records.
IRB ethical approval was provided by the St Vincent’s
Hospital Human Research Ethics Committee (reference number
HREC/14/SVH/291), and informed consent was obtained from
all individual participants included in the study. All procedures
performed in studies involving human participants were in ac-
cordance with the ethical standards of the institutional and/or
national research committee and with the 1964 Helsinki decla-
ration and its later amendments or comparable ethical standards.
Bariatric Operation
A conventional laparoscopic sleeve gastrectomy was per-
formed in all patients. In brief, the patient was placed in the
lithotomy position and pneumoperitoneum created using five
port sites. The liver was elevated using a Nathanson liver
retractor, and the vessels along the greater curvature were
divided using the blunt tip LigaSure™ device (Covidien,
Medtronic, Dublin, Ireland), from a distance of 4–6 cm lateral
to the pylorus to a point 1–2 cm lateral to the gastroesophageal
junction. A hiatus hernia, if present, was repaired with closure
of the diaphragmatic opening using interrupted 0 Ethibond
(Ethicon Inc., Somerville, USA) posterior crural sutures. The
stomach was divided using a motorized linear cutting stapler
device (Echelon Endopath™, Ethicon, Somerville, NJ) over a
32-French bougie for females or a 36-French bougie for
males. The resected stomach was removed through the large
(15 mm) port site. A 10-French Redivac™ drain was left
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adjacent to the staple line, and the wounds were closed with 0-
PDS and 4/0 undyed monocryl. There was no operative mor-
tality and no morbidity.
Blood Collection and Preparation
Fasting blood samples were collected at each study visit. The
blood was spun in a benchtop centrifuge at 1400×g for
10 min. The plasma was then transferred into cryotubes and
stored at −80 °C until analysis.
Cancer-Associated Biomarker Measurement
Two commercially available multiplex bead-based kits
(BioRad, Hercules, CA, USA) were used to measure concen-
trations of 34 biomarkers associated with the development of
cancer in humans. The first assay, the Bio-Plex Pro Human
Cancer Biomarker Panel 1 (171-AC500M), was used to mea-
sure 16 receptors, cytokines, chemokines, growth factors, and
hormones, including soluble epidermal growth factor receptor
(sEGFR), FGF-basic, follistatin, G-CSF, HGF, soluble human
epidermal growth factor 2 (sHER-2/neu), soluble interleukin-
6 receptor alpha (sIL-6Rα), leptin, osteopontin, PECAM-1,
PDGF-AB/BB, prolactin, SCF, sTIE-2, soluble vascular en-
dothelial growth factor receptor (sVEGFR)-1, and sVEGFR-
2. The second assay, the Bio-Plex Pro Human Cancer
Biomarker Panel 2 (171-AC600M), was used to measure 18
cytokines, chemokines, growth factors, and ligands for recep-
tors in Panel 1, including angiopoietin, soluble CD40 ligand
(sCD40L), epidermal growth factor (EGF), endoglin, sFASL,
heparin-binding EGF-like growth factor (HB-EGF), insulin-
like growth factor binding protein-1 (IGFBP-1), interleukin
(IL)-6, IL-8, IL-18, plasminogen activator inhibitor-1 (PAI-
1), placental growth factor (PLGF), transforming growth fac-
tor alpha (TGFα), TNF-α, urokinase plasminogen activator
(uPA), vascular endothelial growth factor (VEGF)-A, VEGF-
C, and VEGF-D.
Plasma protein biomarker levels were quantified at the
Australian Proteome Analysis Facility at Macquarie
University, Sydney, Australia, according to a an optimized
process described previously [22], run in duplicate on 96-
well plates using 50 μL of neat plasma per assay plate. The
standards and samples were dispensed using a robotic liquid
handling workstation (epMotion 5075, Eppendorf, Germany);
plates were washed with Bio-Plex Pro II wash station (Bio-
Rad, CA, USA). Samples were analyzed and standard curves
[log(x) − linear(y)] were generated using the Bio-Plex
Manager v5.0 software (Bio-Rad, CA, USA).
Statistical Analysis
Where necessary, data were log2-transformed to fit normal
distribution. Differences between continuous variables
measured at baseline and at 12-week follow-up were analyzed
using paired t tests. Categorical variables were compared
using McNemar’s test. Correlation analysis of plasma levels
of measured biomarkers and patient BMIs was performed
through linear regression as well as analysis of Pearson’s prod-
uct moment correlation coefficient. A value of p < 0.05 was
considered statistically significant. Data are presented as mean
with standard deviation (SD) unless denoted otherwise. All
analyses were performed using R version 3.2.2 (R
Foundation for Statistical Computing, Vienna, Austria).
Results
Participant Characteristics
Fifteen patients (eight males, seven females) were recruited to
this study. Patient demographics at baseline and at 12 weeks
after laparoscopic sleeve gastrectomy are summarized in
Table 1. The median values (not shown in Table 1) were sim-
ilar to the mean values: mean age was 50.9 years (SD 11.9),
with an average preoperative weight of 122.3 kg (SD 30.7 kg)
and a resulting mean cohort BMI of 42.3 kg/m2 (SD 8.2 kg/
m2). All but two patients, both of whom were morbidly obese
(BMI > 40 kg/m2), had at least one obesity-related comorbid
illness.
Weight Loss Following LSG at 12-weeks Follow-up
The median length of follow-up was 12 weeks (range 11–
13 weeks). At last follow-up, mean weight loss was
20.25 kg (range 9.8–31 kg), with a mean reduction in BMI
of 7.0 kg/m2 (SD 2.4) and a mean percent excess body weight
loss (%EBWL) of 44 % (SD 11 %) (Table 1). There were
reductions in all of the obesity-related comorbidities at 12-
week follow-up, but only one of these was of statistical
significance.
Changes in Cancer-Associated Plasma Biomarkers
Following LSG
Significant reductions were observed for 17 of the 34 bio-
markers measured. These are summarized in Table 2, grouped
according to their primary associations in the literature with
the ‘Hallmarks of Cancer’ [14]. Significant reductions were
observed for all members of the VEGF family (VEGF-A,
VEGF-C, VEGF-D, and PLGF), but not their corresponding
receptors (sVEGFR1, sVEGFR2). A significant reduction in
all of the adipokines and proinflammatory biomarkers (IL-6,
IL-18, TNFα, PAI-1, IL-8, and sCD40L), except leptin, was
observed. Similar to the angiogenic biomarkers, the cytokine
IL-6 was significantly reduced at follow-up, but not its corre-
sponding receptor sIL-6Rα. All members of the epidermal
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growth factor family (EGF, TGFα, and HB-EGF) were sig-
nificantly reduced, but neither of their related receptors
(sEGFR and sHER2/neu) showed significant changes at fol-
low-up. Expression levels of the 17 significantly reduced pro-
teins at baseline and follow-up are shown in Fig. 1.
Discussion
In this study, we found a marked decrease in the levels of
circulating human cancer-associated proteins following lapa-
roscopic sleeve gastrectomy. Half (17/34) of the cancer bio-
markers studied were significantly reduced, and levels of the
remaining proteins had also decreased. This effect was
achieved early, at only 12 weeks after operation, which is
presumably due to the rapidity of weight loss and amelioration
of metabolic disease after effective bariatric surgery; by
12 weeks, the patients had already lost a mean 20 kg, equating
to 44 % loss of excess body weight. We provide evidence
demonstrating that bariatric surgery may significantly reduce
expression of the molecular pathways thought to be associated
with obesity and cancer. Whether this finding is of clinical
significance is as yet unknown. Our results, however, provide
insights as to how bariatric surgery may be an effective meth-
od of cancer prevention, as has been demonstrated in large
clinical studies [8–10].
This study investigated a broad spectrum of biomarkers
causally implicated in cancer development pathways, but of
uncertain prognostic or diagnostic value. Our findings are in
accordance with previously reported factors in the bariatric
literature, including VEGF-A [17], IL-6 [21], TNFα [21],
IL-8 [18], IL-18 [19], PAI-1 [20], sCD40L [23], and prolactin
[24]. Some related protein families associated with specific
molecular pathways are also novel findings here, including
the VEGF and EGF families. The contribution of each path-
way to carcinogenesis in obesity cannot be assessed in this
nonmechanistic descriptive study, but the changes induced by
surgery in this study seem sufficiently large to suggest that at
least some of the molecular pathways are being deactivated,
presumably by reducing the adipose tissue mass and other
factors such as reduced insulin and insulin receptor signaling.
The current understanding of the relationship between ex-
cess body fat and cancer is that metabolically active visceral
adipose tissue induces an upregulation of the molecular path-
ways involved in inflammation, insulin resistance, angiogen-
esis, and the expression of adipokines and other growth fac-
tors [11, 12]. As many of the downstream products of these
pathways have been variously implicated in providing a tissue
microenvironment favorable for the development of cancer,
alterations following bariatric surgery offer insights into the
reversibility of some of these processes. Consequently, it
should be possible to demonstrate biological plausibility for
the reduction of cancer risk and mortality observed in clinical
studies [8–10].
In our panel of 34 cancer-associated plasma biomarkers, 12
have been implicated in angiogenesis. Silha et al. [25] have
Table 1 Demographic,
anthropometric, and obesity-
related comorbid illness variables
in obese participants at baseline
and 12 weeks after laparoscopic
sleeve gastrectomy




Male 8 8 –
Female 7 7 –
Age (years) 50.9 ± 11.9 50.9 ± 11.8 –
Anthropometrica
Weight (kg) 122.3 ± 30.7 102.1 ± 24.4 < 0.001
BMI (kg/m2) 42.3 ± 8.2 35.3 ± 6.4 < 0.001
EBW (kg) 50.3 ± 26.4 30.03 ± 20.4 < 0.001
Weight loss (kg) – 20.25 –
EBWL (%) – 44 ± 11 –
Obesity-related comorbid illnessb
T2DM 6 (40 %) 2 (13 %) 0.11
Hypertension 7 (47 %) 4 (33 %) 0.35
Hyperlipidemia 5 (33 %) 4 (33 %) 0.13
OSA 12 (80 %) 10 (66 %) 0.09
GERD 4 (33 %) 1 (7 %) 0.02
Unless otherwise stated, data are mean ± SD
OSA obstructive sleep apnea, T2DM type 2 diabetes mellitus, GERD gastroesophageal reflux disease
a Comparisons are by paired t tests
b Comparisons are by McNemar’s test
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previously reported that, of the angiogenic biomarkers rele-
vant to our study, VEGF-A, VEGF-C, VEGF-D, sVEGFR2,
and angiopoietin-2 are elevated in obese subjects compared to
normal controls. We showed a significant decrease in all of the
VEGF family of growth factors studied, including PLGF, but
not their corresponding receptors following laparoscopic
sleeve gastrectomy (LSG). This expands on a previous study
that demonstrated a reduction in VEGF-A up to 1 year follow-
ing vertical banded gastroplasty, gastric bypass, and
biliopancreatic diversion [17]. In addition, we observed a
significant reduction in endoglin, a transmembrane accessory
receptor for the cytokine TGF-β. Endoglin stimulates prolif-
eration and migration of vascular endothelial cells in vivo via
activation of the activin receptor-like kinase 1 (ALK1) path-
way [26]. Increased expression has been demonstrated in the
angiogenic endothelial cells of human tumor samples [27] and
correlated with the high white adipose tissue burden in obese
rodent models [28]. Considered together, these results suggest
that the proangiogenic cascade is reversible and this change
occurs early after bariatric surgery.
Table 2 Alterations in plasma levels of 34 cytokines, ligands, growth factors, hormones, and their receptors at baseline and 12 weeks after
laparoscopic sleeve gastrectomy
Hallmark of cancer Cytokines, ligands, growth factors, and hormones Corresponding receptors
Variable Baseline 12 weeks after LSG p value Variable Baseline 12 weeks after LSG p value
Angiogenesis Vascular endothelial growth factor (VEGF) superfamily
VEGF-A 129.6 ± 26.7 107.7 ± 32.4 0.01 sVEGFR1 79.2 ± 29.9 85.8 ± 43.0 0.53
VEGF-C 494.43 ± 84.4 434.6 ± 96.1 0.02 sVEGFR2 780.1 ± 275.7 707.5 ± 138.3 0.62
VEGF-D 228.3 ± 33.0 206.5 ± 42.3 0.04
PLGF 50.7 ± 10.4 43.6 ± 11.0 0.02
Other vascular growth factors
Angiopoietin-2 540.1 ± 242.2 531.7 ± 339.0 0.47 sTIE-2 3293.9 ± 2602.2 2977.9 ± 2339.0 0.49
Endoglin 294.4 ± 70.8 254 ± 80.5 0.03
PDGF-AB/BB 91.7 ± 35.1 76.6 ± 19.5 0.26
G-CSF 87.7 ± 37.0 90.9 ± 47.3 0.96
FGF-basic 62.2 ± 17.7 63.5 ± 17.7 0.88
Inflammation Adipokines
IL-6 45.1 ± 10.2 37.1 ± 11.0 0.008 sIL-6Rα 121.3 ± 111.2 104.2 ± 111.6 0.69
IL-18 88.6 ± 33.0 54.5 ± 58.7 0.003
TNFα 40.0 ± 8.1 34.1 ± 10.3 0.02
Leptin 122.0 ± 45.3 105.6 ± 21.2 0.34
Other proinflammatory biomarkers
PAI-1 3135.2 ± 1390.1 2251.0 ± 1266.4 0.003 uPA 194.8 ± 60.6 184.7 ± 62.1 0.24
IL-8 10.9 ± 2.9 8.7 ± 2.7 0.005
sCD40L 106.1 ± 25.7 87.7 ± 27.2 0.01
Cell proliferation Epidermal growth factor family
EGF 17.7 ± 6.4 8.3 ± 12.1 0.003 sEGFR 579.6 ± 245.6 578.8 ± 96.0 0.55
TGFα 47.6 ± 11.1 32.0 ± 40.7 0.03 sHER2/neu 67.3 ± 51.1 53.9 ± 30.4 0.31
HB-EGF 26.1 ± 5.5 21.9 ± 6.2 0.01
Hormones associated with obesity and insulin resistance
Prolactin 959.6 ± 485.1 449.3 ± 593.5 0.004
IGFBP-1 1268.6 ± 421.9 717.8 ± 1023.8 0.02
Other growth factors
Follistatin 309.0 ± 148.7 278.5.0 ± 104.2 0.72
HGF 320.9 ± 171.6 281.8 ± 79.3 0.7
SCF 41.8 ± 10.5 41.0 ± 9.4 0.89
Cell adhesion PECAM-1 289.4 ± 149.0 249.5 ± 96.6 0.3
Apoptosis sFASL 224.0 ± 36.6 196.6 ± 39.0 0.03
Metastasis Osteopontin 1912.5 ± 1330.0 1858.9 ± 1686.9 0.61
The biomarkers are grouped according to their best match for one of the BHallmarks of Cancer^after LSG; many are associated with more than one
BHallmark.^ Data are mean ± SD. Comparisons are by paired t tests
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Of the ligands that bind to the epidermal growth factor
receptor (EGFR) family of receptor tyrosine kinases associat-
ed with cell proliferation [29], we observed a decrease in EGF,
TGFα, and heparin-binding EGF-like growth factor
(HBEGF). Neither sEGFR (ErbB) nor sHER2/neu (ErbB2),
their corresponding soluble receptors, were significantly al-
tered. EGF, TGFα, and HBEGF have all been associated with
cancer. Of these, HBEGF is abundantly expressed in human
adipose tissue [30], TGFα has been implicated in the devel-
opment of obesity-related postmenopausal breast cancer using
rodent models [31], and EGF has received much attention as a
therapeutic target in anticancer therapies [32]. If the produc-
tion of these ligands is upregulated in obesity, there are signif-
icant implications for EGFR-mediated cell proliferation, inva-
sion, and metastasis of epithelial malignancies via down-
stream activation of the ERK, PI3 kinase/AKT, and JAK/
STAT pathways [32, 33]. Expression of TGFα, EGF, and
EGFR worsens prognosis and increases the metastatic poten-
tial of breast [34], renal [35], and colorectal cancers [36], all
known to be obesity-associated malignancies. Altered expres-
sion of these ligands has not been previously reported follow-
ing bariatric surgery.
The chronic, low-grade inflammatory state associated with
obesity is strongly suspected to play an integral role in the
development of malignancy. The upregulation of inflammato-
ry cytokines in obesity has been extensively investigated and
is thought to be related to the production of adipokines [37],
infiltration of inflammatory immune cells [38], and tissue hyp-
oxia associated with the proliferation of adipose tissue [39].
The inflammatory mediators and adipokines IL-6, IL-8, and
TNFα were significantly reduced in our investigation,
confirming the findings of previous bariatric surgery studies,
including LSG [14, 21, 40]. All three have been implicated in
tumor proliferation, angiogenesis, and metastasis via activa-
tion of multiple upstream pathways, including STAT3 [41],
CXCR1 and CXCR2 [42], and NF-κB [43], respectively.
Additionally, the SERPINE1 gene transcript PAI-1, an inflam-
matory cytokine also implicated in angiogenesis and metasta-
sis through extracellular matrix remodeling [44], was signifi-
cantly decreased following bariatric surgery in our study.
Decreased expression has similarly been demonstrated up to
6 months following LSG [20].
The inflammatory-related proteins should be consid-
ered together with the less well-established markers of
inflammation included in our panel, such as FasL and
sCD40L. The novel finding of significantly reduced Fas-
ligand (FasL) levels reported here is linked to obesity;
increased expression of FasL has been associated with
adipocyte hypertrophy and macrophage infiltration in ad-
ipose tissue [45], for example. FasL is known to induce
apoptosis by binding the death receptor Fas (CD95) [46]
but may have an additional nonapoptotic inflammatory
role via induction of gene expression for the ERK, JNK,
and NF-κB pathways [47], in addition to increasing ex-
pression of the IL-1β, IL-6, and MCP-1 cytokines [48].
The cytokine sCD40L was also significantly reduced with
surgical weight loss. In vivo studies of human cancers
have demonstrated higher levels of the cytokine sCD40L
secondary to tumor-induced platelet activation [49].
Traditionally, this was thought to promote angiogenesis
via activation of the CD40/CD40L pathway [49], but more
recently, an immunosuppressive effect secondary to in-
flammation has been proposed [50]. The observed reduc-
tion of sCD40L in our study would support both hypoth-
eses given the reduction in the other proangiogenic bio-
markers studied and the known secondary immunosup-
pression caused by inflammation in obesity [51].
It is plausible that the results of our study may be alterna-
tively explained by a resolution of insulin resistance following
LSG. Although most of the patients did not have insulin re-
sistance or T2DM, it is well known that raised systemic insu-
lin levels can potentiate anabolic effects to mediate cell pro-
liferation and enhance tumor growth [52]. Related to this hy-
pothesis, our finding of decreased IGFBP-1 following LSG is
of uncertain significance. A recent review [53] found that
there is a lack of evidence for IGFBP-1 stimulating tumor
growth or cell migration, and that it may in fact play a role
in tumor growth inhibition.
Limitations of the present study include the relatively
small sample size. A study with later follow-up may also
find more statistically significant changes. The nonsignif-
icant result for leptin, for example, is at odds with similar
bariatric surgery studies that included more patients [14].
The present study also lacks the large cohort of healthy
weight (BMI < 25 kg/m2) controls that would be required,
at a considerable reagent cost, to establish normal values
for these biomarkers. Of the cancer-associated biomarkers
we have measured, the National Cancer Institute has ap-
proved only four for routine clinical use in the context of
breast cancer: mutations in EGFR, HER2/neu gene over-
expression, as well as uPA and PAI-1 [54]. Areas for fu-
ture study include the ongoing elucidation of the biologi-
cal function of these gene products and pathways in
healthy and overweight or obese individuals, longer term
follow-up, and a comparison of the expression human can-
cer biomarkers in obese and healthy weight patients un-
dergoing nonbariatric surgery.
Conclusion
Effective weight loss, which is most reliably provided in
obese individuals by bariatric surgery, results in a rapid
decrease in the measured levels of cancer-associated cir-
culating proteins. This suggests that obesity-associated
carcinogenic processes may be directly attenuated by
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bariatric surgery, which can thus be considered to pro-
vide a cancer prevention role in the obese.
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